Phase i trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma

Daruka Mahadevan, Donald W. Northfelt, Pavani Chalasani, Diane Rensvold, Sandra Kurtin, Daniel D. Von Hoff, Mitesh J. Borad, Raoul Tibes

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objectives: UNBS5162 is a novel naphthalimide that binds to DNA by intercalation and suppresses CXCL chemokine elaboration. A Phase I study of UNBS5162 was conducted to establish pharmacokinetics (PK), maximum tolerated dose (MTD), dose-limiting toxicity, safety and anti-tumor activity in patients with advanced solid tumors or lymphoma. Methods: UNBS5162 was administered in a 3 + 3 dose escalation scheme by intravenous infusion over 1 h weekly for 3 weeks of a 4-week cycle. Safety, serial serum PK and tolerability were captured throughout the study. Response Evaluation Criteria in Solid Tumors was utilized every 2 cycles to assess for anti-tumor response. Results: Twenty-four patients with metastatic carcinoma and 1 patient with lymphoma were treated at eight dose levels (18-234 mg/m2). All patients were evaluable for tolerability and toxicity. Grade 3 toxicities include nausea (n = 1), fatigue (n = 1) and anorexia (n = 1). Prolongation of QTc [Hodges] was observed in 6 cases (Gr 1 = 2; Gr 2 = 2; Gr 3 = 2). C max and area under the curve increased linearly with dose with a t 1/2 of 30-60 min. 16 patients completed 2 cycles of therapy, all with pharmacodynamics at 8 weeks. Conclusions: The MTD or dose-limiting toxicity for UNBS5162 was not reached due to the magnitude of QTc prolongation at the highest dose of 234 mg/m2/week that led to study termination.

Original languageEnglish (US)
Pages (from-to)934-941
Number of pages8
JournalInternational Journal of Clinical Oncology
Volume18
Issue number5
DOIs
StatePublished - Oct 2013

Fingerprint

Naphthalimides
Lymphoma
Maximum Tolerated Dose
Neoplasms
Pharmacokinetics
Safety
Anorexia
Chemokines
Intravenous Infusions
Nausea
Area Under Curve
Fatigue
UNBS 5162
Carcinoma
DNA
Serum

Keywords

  • Chemokines
  • Dose-limiting toxicity
  • Maximum tolerated dose
  • Naphthalimide
  • QTc

ASJC Scopus subject areas

  • Oncology
  • Surgery
  • Hematology

Cite this

Phase i trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma. / Mahadevan, Daruka; Northfelt, Donald W.; Chalasani, Pavani; Rensvold, Diane; Kurtin, Sandra; Von Hoff, Daniel D.; Borad, Mitesh J.; Tibes, Raoul.

In: International Journal of Clinical Oncology, Vol. 18, No. 5, 10.2013, p. 934-941.

Research output: Contribution to journalArticle

Mahadevan, Daruka ; Northfelt, Donald W. ; Chalasani, Pavani ; Rensvold, Diane ; Kurtin, Sandra ; Von Hoff, Daniel D. ; Borad, Mitesh J. ; Tibes, Raoul. / Phase i trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma. In: International Journal of Clinical Oncology. 2013 ; Vol. 18, No. 5. pp. 934-941.
@article{23450ea87a484996a03dafa289609111,
title = "Phase i trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma",
abstract = "Objectives: UNBS5162 is a novel naphthalimide that binds to DNA by intercalation and suppresses CXCL chemokine elaboration. A Phase I study of UNBS5162 was conducted to establish pharmacokinetics (PK), maximum tolerated dose (MTD), dose-limiting toxicity, safety and anti-tumor activity in patients with advanced solid tumors or lymphoma. Methods: UNBS5162 was administered in a 3 + 3 dose escalation scheme by intravenous infusion over 1 h weekly for 3 weeks of a 4-week cycle. Safety, serial serum PK and tolerability were captured throughout the study. Response Evaluation Criteria in Solid Tumors was utilized every 2 cycles to assess for anti-tumor response. Results: Twenty-four patients with metastatic carcinoma and 1 patient with lymphoma were treated at eight dose levels (18-234 mg/m2). All patients were evaluable for tolerability and toxicity. Grade 3 toxicities include nausea (n = 1), fatigue (n = 1) and anorexia (n = 1). Prolongation of QTc [Hodges] was observed in 6 cases (Gr 1 = 2; Gr 2 = 2; Gr 3 = 2). C max and area under the curve increased linearly with dose with a t 1/2 of 30-60 min. 16 patients completed 2 cycles of therapy, all with pharmacodynamics at 8 weeks. Conclusions: The MTD or dose-limiting toxicity for UNBS5162 was not reached due to the magnitude of QTc prolongation at the highest dose of 234 mg/m2/week that led to study termination.",
keywords = "Chemokines, Dose-limiting toxicity, Maximum tolerated dose, Naphthalimide, QTc",
author = "Daruka Mahadevan and Northfelt, {Donald W.} and Pavani Chalasani and Diane Rensvold and Sandra Kurtin and {Von Hoff}, {Daniel D.} and Borad, {Mitesh J.} and Raoul Tibes",
year = "2013",
month = "10",
doi = "10.1007/s10147-012-0475-8",
language = "English (US)",
volume = "18",
pages = "934--941",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Phase i trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma

AU - Mahadevan, Daruka

AU - Northfelt, Donald W.

AU - Chalasani, Pavani

AU - Rensvold, Diane

AU - Kurtin, Sandra

AU - Von Hoff, Daniel D.

AU - Borad, Mitesh J.

AU - Tibes, Raoul

PY - 2013/10

Y1 - 2013/10

N2 - Objectives: UNBS5162 is a novel naphthalimide that binds to DNA by intercalation and suppresses CXCL chemokine elaboration. A Phase I study of UNBS5162 was conducted to establish pharmacokinetics (PK), maximum tolerated dose (MTD), dose-limiting toxicity, safety and anti-tumor activity in patients with advanced solid tumors or lymphoma. Methods: UNBS5162 was administered in a 3 + 3 dose escalation scheme by intravenous infusion over 1 h weekly for 3 weeks of a 4-week cycle. Safety, serial serum PK and tolerability were captured throughout the study. Response Evaluation Criteria in Solid Tumors was utilized every 2 cycles to assess for anti-tumor response. Results: Twenty-four patients with metastatic carcinoma and 1 patient with lymphoma were treated at eight dose levels (18-234 mg/m2). All patients were evaluable for tolerability and toxicity. Grade 3 toxicities include nausea (n = 1), fatigue (n = 1) and anorexia (n = 1). Prolongation of QTc [Hodges] was observed in 6 cases (Gr 1 = 2; Gr 2 = 2; Gr 3 = 2). C max and area under the curve increased linearly with dose with a t 1/2 of 30-60 min. 16 patients completed 2 cycles of therapy, all with pharmacodynamics at 8 weeks. Conclusions: The MTD or dose-limiting toxicity for UNBS5162 was not reached due to the magnitude of QTc prolongation at the highest dose of 234 mg/m2/week that led to study termination.

AB - Objectives: UNBS5162 is a novel naphthalimide that binds to DNA by intercalation and suppresses CXCL chemokine elaboration. A Phase I study of UNBS5162 was conducted to establish pharmacokinetics (PK), maximum tolerated dose (MTD), dose-limiting toxicity, safety and anti-tumor activity in patients with advanced solid tumors or lymphoma. Methods: UNBS5162 was administered in a 3 + 3 dose escalation scheme by intravenous infusion over 1 h weekly for 3 weeks of a 4-week cycle. Safety, serial serum PK and tolerability were captured throughout the study. Response Evaluation Criteria in Solid Tumors was utilized every 2 cycles to assess for anti-tumor response. Results: Twenty-four patients with metastatic carcinoma and 1 patient with lymphoma were treated at eight dose levels (18-234 mg/m2). All patients were evaluable for tolerability and toxicity. Grade 3 toxicities include nausea (n = 1), fatigue (n = 1) and anorexia (n = 1). Prolongation of QTc [Hodges] was observed in 6 cases (Gr 1 = 2; Gr 2 = 2; Gr 3 = 2). C max and area under the curve increased linearly with dose with a t 1/2 of 30-60 min. 16 patients completed 2 cycles of therapy, all with pharmacodynamics at 8 weeks. Conclusions: The MTD or dose-limiting toxicity for UNBS5162 was not reached due to the magnitude of QTc prolongation at the highest dose of 234 mg/m2/week that led to study termination.

KW - Chemokines

KW - Dose-limiting toxicity

KW - Maximum tolerated dose

KW - Naphthalimide

KW - QTc

UR - http://www.scopus.com/inward/record.url?scp=84886088518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886088518&partnerID=8YFLogxK

U2 - 10.1007/s10147-012-0475-8

DO - 10.1007/s10147-012-0475-8

M3 - Article

C2 - 23053399

AN - SCOPUS:84886088518

VL - 18

SP - 934

EP - 941

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 5

ER -